摘要
目的观察尼麦角林联合盐酸多奈哌齐对阿尔茨海默病患者认知功能、日常生活能力及安全性的影响。方法将98例阿尔茨海默病患者随机分为治疗组与对照组各49例。对照组每日口服盐酸多奈哌齐5 mg,每日1次,治疗组在对照组的基础上口服尼麦角林20 g,每日3次。比较两组患者治疗前与治疗后3个月、6个月时认知功能评分(MMSE、ADAS-cog)、阿尔茨海默病日常生活能力合作研究量表(ADAS-ADL)、血清一氧化氮(NO)、前列环素(PG)I2水平及不良反应发生率。结果与对照组相比,治疗组治疗后6个月的MMSE评分、治疗后3个月的ADAS-cog评分和治疗后3个月、6个月的ADCS-ADL评分有显著性差异(P<0.05)。治疗前两组NO和PGI2水平无显著性差异(P>0.05),治疗后3个月和6个月治疗组与对照组NO、PGI2有显著性差异(P<0.05)。MMSE评分与NO和PGI2水平呈负相关(r=-0.893、-0.580,均P<0.001)。治疗组与对照组不良反应发生率差异无统计学意义(P>0.05)。结论尼麦角林联合盐酸多奈哌齐治疗方案可提高阿尔茨海默病患者日常生活能力及认知功能,安全性较好,其机制可能是通过减少神经毒性物质NO及PGI2的产生。
Objective To observe the effects of nicergoline combined with donepezil hydrochloride on cognitive function, daily living ability and safety in patients with Alzheimer′s disease(AD).Methods 98 AD patients with were randomly divided into treatment group and control group, 49 cases in each group. The control group was given 5 mg donepezil hydrochloride orally once a day, and the treatment group was given 20 g nicergoline orally after meals on the basis of the control group, three times a day. The cognitive function score(MMSE, ADAS-cog), daily life ability score(ADAS-ADL),serum nitric oxide(NO), prostaglandin(PG)I2 levels and the incidence of adverse reactions, were compared between the two groups before and 3 months and 6 months after treatment.Results Compared with the control group, MMSE score at 6 months after treatment, ADAS-COG score at 3 months after treatment, and ADCS-ADL score at 3 months and 6 months after treatment were significantly different in the treatment group(P<0.05). There was no significant difference in NO level and PGI2 level between the two groups before treatment(P>0.05).There were significant differences in NO and PGI2 levels between the two groups at 3 and 6 months after treatment(P<0.05).MMSE scores were negatively correlated with NO and PGI2 levels(r=-0.893,-0.580,all P<0.001).There was no significant difference in the incidence of adverse reactions between the treatment group and the control group(P>0.05).Conclusions Nicergoline combined with donepezil hydrochloride could improve daily living and cognitive function in AD,with good safety, the mechanism may be by reducing the production of neurotoxic substances NO and PGI2.
作者
黄攀
何晓英
徐敏
HUANG Pan;HE Xiao-Ying;XU Min(Department of Internal Neurology,People's Hospital of Deyang City,Deyang 618000,Sichuan,China)
出处
《中国老年学杂志》
CAS
北大核心
2022年第3期611-614,共4页
Chinese Journal of Gerontology
基金
国家“十一五”科技支撑重大专项基金资助项目(2006BAI04A02)
四川省卫生厅一般资助项目(08013)
四川省应用基础研究计划项目(2014JC0166)
四川省卫生厅资助项目(110368)
四川省科技厅资助项目(16ZD046)。
